Jul 2009 to 2000 CFO/ControllerMain Street Restaurant Partners New York, NY Nov 2005 to Jul 2009 CFO/PartnerTony May Group New York, NY May 1997 to Nov 2005 CFO/ControllerArcimboldo Restaurant & Cornucopia Catering Company New York, NY Oct 1995 to May 1997 ControllerCafe Concepts, Inc New York, NY Dec 1994 to Oct 1995 ControllerHospitality Management Systems, Inc
Mar 1993 to Nov 1994 Computer ConsultantHarry Cipriani & Bellini By Cipriani New York, NY Oct 1988 to Mar 1993 ControllerCafe Argenteuil New York, NY Jun 1986 to Sep 1988 Controller
Pomme Group Real Estate Corp. New York, NY 7183003656 (Phone)
Interests:
Historic properties antiques classic cars
About:
Richard is a native New Yorker and successful entrepreneur who has founded and served as President and Senior Executive of several companies including the Nation’s two largest Healthcare Systems. His experience in LEED (green) building technologies both in new construction and historic restoration stems from his position as Executive Director and Chief Development Officer of New York’s oldest National Landmark Museum, where he directed the five building restoration alongside renowned preservation architects, craftsmen and suppliers of special products and technologies…with funds he secured from Fortune 50 companies, government grants and private foundations. Richard has managed his own real estate portfolio for decades which included a 1716 Virginia Historic Estate, a Victorian Seashore Colonial and Town Homes in New Jersey. He draws on his vast experience, exemplary knowledge and resources to seek out the right property…for the discerningly and diverse clientele who seek his guidance in buying, selling and rental of high-end New York and international properties. Richard believes in giving back to the community and serves on a number of non profit boards which support the preservation of history, foster education and promote philanthropy. He was inducted into the National Gavel Society in 2009.
Neurological Associates Of St Paul PAHealtheast Neurosurgery Clinic 17 Exchange St W STE 850, Saint Paul, MN 55102 6512323900 (phone), 6512323956 (fax)
Education:
Medical School University of Minnesota Medical School at Minneapolis Graduated: 1968
Procedures:
Craniotomy Spinal Cord Surgery Spinal Fusion Spinal Surgery
Conditions:
Intervertebral Disc Degeneration
Languages:
English
Description:
Dr. Gregory graduated from the University of Minnesota Medical School at Minneapolis in 1968. He works in Saint Paul, MN and specializes in Surgery , Neurological. Dr. Gregory is affiliated with Healtheast St Josephs Hospital.
Institute Of Aesthetic Surgery 400 Celebration Pl STE A320, Kissimmee, FL 34747 4074098000 (phone), 8667607840 (fax)
Education:
Medical School Indiana University School of Medicine Graduated: 1971
Conditions:
Abdominal Hernia Breast Disorders Cholelethiasis or Cholecystitis Malignant Neoplasm of Female Breast
Languages:
English
Description:
Dr. Gregory graduated from the Indiana University School of Medicine in 1971. He works in Kissimmee, FL and specializes in Plastic Surgery. Dr. Gregory is affiliated with Florida Hospital Celebration Health and Florida Hospital Orlando.
The present invention relates to transgene expression systems, related compositions comprising the transgene expression systems, and methods of making and using them. Preferred systems employ an adenovirus transgene expression vector comprising DNA encoding a transgene which codes for a desired product operably linked to expression control sequence, and at least a portion of the adenovirus E3 region and certain portions of the E4 region. The E4 portions comprise the open reading frame sequence known as E40RF3 and at least one other portion of E4. Preferably the E4 portion of the vector (or âE4 cassetteâ) includes E40RF3 and at least one other portion selected from E40RF4, E40RF6/7 and E40RF3/4. The invention has a number of important features including improving persistency of transgene expression in a desired host cell. The transgene expression systems of the present invention are useful for a variety of applications including providing persistent cellular expression of the transgene in vitro and in vivo.
The present invention relates to transgene expression systems, related compositions comprising the transgene expression systems, and methods of making and using them. Preferred systems employ an adenovirus transgene expression vector comprising DNA encoding a transgene which codes for a desired product operably linked to expression control sequence, and at least a portion of the adenovirus E3 region and certain portions of the E4 region. The E4 portions comprise the open reading frame sequence known as E4ORF3 and at least one other portion of E4. Preferably the E4 portion of the vector (or âE4 cassetteâ) includes E4ORF3 and at least one other portion selected from E4ORF4, E4ORF6/7 and E4ORF3/4. The invention has a number of important features including improving persistency of transgene expression in a desired host cell. The transgene expression systems of the present invention are useful for a variety of applications including providing persistent cellular expression of the transgene in vitro and in vivo.
Antibodies Specific For Cystic Fibrosis Transmembrane Conductance Regulator And Uses Therefor
Seng H. Cheng - Bosaton MA John Marshall - Milford MA Richard J. Gregory - Ayer MA Patrick W. Rafter - Natick MA
Assignee:
Genzyme Corporation - Cambridge MA
International Classification:
C07K 1628 C12N 518
US Classification:
5303882
Abstract:
Antibodies for binding epitopes of cystic fibrosis transmembrane conductance regulator (CFTR) and hybridomas which produce such antibodies are described. The antibodies of the present invention can be used in a method for detecting CFTR in a biological sample and/or in a method for purifying CFTR from an impure solution. In addition, the present invention includes a method for detecting CFTR in a biological sample from a nonhuman cystic fibrosis knockout animal wherein the the nonhuman cystic fibrosis knockout animal has been subjected to human CFTR replacement therapy. Another aspect of the present invention is a method for determining the orientation of CFTR in the membrane of a lipid vesicle. Yet another aspect of the invention is a kit for detecting CFTR in a biological sample.
Walter R. Marshall - Bloomfield NJ Richard A. Gregory - Belle Mead NJ Richard H. Handwerk - South Somerville NJ
Assignee:
Union Carbide Corporation - New York NY
International Classification:
B01D 2126
US Classification:
210 84
Abstract:
Process is disclosed for effecting phase separation of relatively high and low viscosity immiscible liquids comprising maintaining, between inner means in relative rotational movement with outer sleeve means, at least one zone of increased pressure constriction and of decreased pressure constriction; feeding a multiphase mixture of relatively low viscosity and relatively high viscosity liquids to the interior of said sleeve means between said zones of increased and decreased pressure constriction; and withdrawing said high viscosity liquid and said low viscosity liquid from the vicinities of said zones of increased and decreased pressure constriction, respectively.
Johanne Kaplan - Sherborn MA Donna Armentano - Belmont MA Richard J. Gregory - Westford MA
Assignee:
Genzyme Corporation - Cambridge MA
International Classification:
C12N 1586 C07J 900
US Classification:
4353201
Abstract:
The present invention relates to transgene expression systems, related pharmaceutical compositions, and methods of making and using them. Preferred systems employ an adenovirus transgene expression vector comprising DNA sequence encoding a transgene which codes for a desired product, expressibly contained within an adenovirus vector containing at least a portion of the E3 region and certain portions of the E4 region. The E4 portions comprise the open reading frame sequence known as E4ORF3 and at least one other portion of E4. Preferably the E4 portion of the vector (or "E4 cassette") includes E4ORF3 and at least one other portion selected from E4ORF4, E4ORF6/7 and E4ORF3/4. The invention has a number of important features including improving persistency of transgene expression in a desired host cell. The transgene expression systems of the present invention are useful for a variety of applications including providing persistent cellular expression of the transgene in vitro and in vivo.
Organ-Specific Targeting Of Cationic Amphiphile / Dna Complexes For Gene Therapy
Ronald K. Scheule - Hopkinton MA Rebecca G. Bagley - Natick MA Simon J. Eastman - Hudson MA Seng H. Cheng - Wellesley MA John Marshall - Hopedale MA David J. Harris - Lexington MA Edward R. Lee - Natick MA Craig S. Siegel - Woburn MA S. Catherine Hubbard - Belmont MA Duane E. Johnson - Encinitas CA Daniel C. Maneval - San Diego CA H. Michael Shepard - Rancho Santa Fe CA Richard J. Gregory - Westford MA
Assignee:
Genzyme Corporation - Framingham MA
International Classification:
A61K 4800 C12N 1588 C12N 1563
US Classification:
514 44
Abstract:
Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from alkyl or acyl groups; and cationic groups, protonatable at physiological pH, derived from amines, alkylamines or polyalkylamines. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile. Novel and highly effective plasmid constructs are also disclosed, including those that are particularly effective at providing gene therapy for clinical conditions complicated by inflammation.
- Paris, FR Kevin Brower - Holliston MA, US Patrick Finn - Franklin MA, US Richard C. Gregory - Framingham MA, US Rao Koduri - Shrewsbury MA, US Feng Liu - San Diego CA, US Natalia Malkova - Needham MA, US Parminder Mankoo - Foster City CA, US Jack R. Pollard - Acton MA, US Huawei Qiu - Westborough MA, US Joachim Theilhaber - Cambridge MA, US Christopher Winter - Swampscott MA, US Marcella Yu - Fremont CA, US
The invention provides an improved pan-TGF-β antibody for treatment of conditions that are mediated by TGF-β, including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.
- Paris, FR Kevin Brower - Holliston MA, US Patrick Finn - Franklin MA, US Richard C. Gregory - Framingham MA, US Rao Koduri - Shrewsbury MA, US Feng Liu - San Diego CA, US Natalia Malkova - Needham MA, US Parminder Mankoo - Foster City CA, US Jack R. Pollard - Acton MA, US Huawei Qiu - Westborough MA, US Joachim Theilhaber - Cambridge MA, US Christopher Winter - Swampscott MA, US Marcella Yu - Fremont CA, US
The invention provides an improved pan-TGF-β antibody for treatment of conditions that are mediated by TGF-β, including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.
Isbn (Books And Publications)
The Dollarization Discipline: How to Translate Your Value-Added into Real Money